What does Rolapitant (Varubi) do in plain English—and how does it work inside your body?
Rolapitant is an FDA-regulated Substance P/Neurokinin-1 Receptor Antagonist (RxNorm RxCUI 1665503). Mechanistically, 12.1 Mechanism of Action Rolapitant is a selective and competitive antagonist of human substance P/NK1 receptors. Rolapitant does not have significant affinity for the NK2 or NK3 receptors or for a battery of other receptors, transporters, enzymes and ion channels. Rolapitant is also active in animal models of chemotherapy-induced emesis. [1][2].
When your doctor writes a prescription for Rolapitant (RxNorm RxCUI 1665503, also dispensed under brand names including Varubi), the goal is to target the root physiological pathway driving your condition rather than just masking surface symptoms [1]. According to the official FDA DailyMed package insert, 12.1 Mechanism of Action Rolapitant is a selective and competitive antagonist of human substance P/NK1 receptors. Rolapitant does not have significant affinity for the NK2 or NK3 receptors or for a battery of other receptors, transporters, enzymes and ion channels. Rolapitant is also active in animal models of chemotherapy-induced emesis. [2].
Across real-world patient logs on dotMD (90% positive worth-it rating), patients do best when they understand both what the medication is doing on day 1 and how long it takes to reach steady-state protection [3].
Check the imprint code on your Rolapitant tablet bottle and confirm with your pharmacist that it matches your prescribed strength (90 mg/1 Tablet, Maintenance adjustment for Rolapitant based on hepatic/renal clearance).